CANbridge Pharmaceuticals H1 revenue rises on Hunterase and Livmarli strength
CANbridge Pharmaceuticals says its H1 revenue rose, supported by Hunterase and Livmarli strength.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.